Welcome to our dedicated page for NewAmsterdam Pharma Company N.V news (Ticker: NAMS), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pharma Company N.V stock.
NewAmsterdam Pharma Company N.V. reports news on its late-stage clinical biopharmaceutical work in oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The company’s principal program centers on obicetrapib, an oral, low-dose CETP inhibitor, evaluated alone and as a fixed-dose combination with ezetimibe as an adjunct to statin therapy.
Recurring updates include Phase 3 clinical data from programs such as BROADWAY, TANDEM, BROOKLYN and PREVAIL, safety and tolerability analyses, regulatory-review activity, financial results, corporate presentations and scientific-conference disclosures. NewAmsterdam also reports Nasdaq inducement grants and other equity-compensation actions tied to its public-company governance.
NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement grants of options covering 217,000 ordinary shares to four non-executive new hires under its 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $31.57 (closing price on Feb 2, 2026) and vest over four years: 25% after one year, then 36 equal monthly installments, subject to continued service and plan terms.
NewAmsterdam Pharma (Nasdaq: NAMS) said its CFO Ian Somaiya and EVP Matthew Philippe will take part in a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026 at 8:30 a.m. ET.
A live webcast will be available via the company investor relations site and an archived replay will be posted after the event.
NewAmsterdam Pharma (Nasdaq: NAMS) summarized 2025 progress and 2026 priorities for obicetrapib. Key points: EMA approval decision expected in 2H26 for obicetrapib monotherapy and obicetrapib/ezetimibe FDC; PREVAIL CVOT event rate is tracking in line with BROADWAY; RUBENS Phase 3 began enrollment in Dec 2025 with topline data expected by year-end 2026; a planned Alzheimer’s trial is set to start in 2026; year-end cash and marketable securities were approximately $729 million, which company says should fund operations through the PREVAIL readout and potential US launch.
NewAmsterdam Pharma (Nasdaq:NAMS) announced inducement stock option grants for a newly hired non-executive employee under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The Compensation Committee approved options covering 20,000 ordinary shares with an exercise price of $35.20 per share, equal to the closing Nasdaq price on January 2, 2026. The options vest over four years: 25% on the one-year anniversary of the vesting commencement date, then the remaining shares in 36 equal monthly installments, subject to continued service, and are governed by the 2024 Inducement Plan and an option award agreement.
NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement option grants covering an aggregate of 40,000 ordinary shares to two non‑executive new hires under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options carry an exercise price of $39.61, equal to the closing Nasdaq price on December 1, 2025 (grant date). The shares subject to the options vest over four years: 25% on the one‑year anniversary of each vesting commencement date, then the balance in 36 equal monthly installments, subject to continued service. The options are governed by the 2024 Inducement Plan and individual option award agreements.
NewAmsterdam Pharma (Nasdaq: NAMS) announced that company management will participate in three investor conferences in early December 2025: the 8th Annual Evercore Healthcare Conference on Dec 2, 2025 (Ian Somaiya, CFO, fireside chat at 3:50 PM ET); Citi 2025 Global Healthcare Conference on Dec 3, 2025 (Michael Davidson, CEO, and Ian Somaiya, CFO, fireside chat at 3:15 PM ET); and the Piper Sandler 37th Annual Healthcare Conference on Dec 4, 2025 (Michael Davidson, CEO, and Ian Somaiya, CFO, fireside chat at 8:00 AM ET).
Live webcasts and archived replays of the fireside chats will be available via the company’s investor relations website at ir.newamsterdampharma.com.
NewAmsterdam Pharma (Nasdaq: NAMS) announced that its Compensation Committee approved inducement option grants covering 18,000 ordinary shares to one non-executive new hire under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $37.00, equal to the Nasdaq closing price on the grant date of November 3, 2025. Vesting occurs over four years: 25% on the one-year anniversary of the vesting commencement date, then the remainder in 36 equal monthly installments, subject to continued service. Grants are subject to the 2024 Inducement Plan and the related option award agreement.
NewAmsterdam Pharma (Nasdaq: NAMS) reported third-quarter 2025 results and a corporate update focused on obicetrapib development and regulatory progress.
Key points: EMA accepted MAAs for obicetrapib 10 mg monotherapy and a 10/10 mg obicetrapib/ezetimibe FDC; pooled BROADWAY and BROOKLYN analyses were published in JACC and a BROADWAY Alzheimer’s substudy in Journal of Prevention of Alzheimer's Disease. Cash, cash equivalents and marketable securities were $756.0 million at September 30, 2025; Q3 revenue was $0.3M and net loss was $72.0M.
NewAmsterdam Pharma (Nasdaq: NAMS) will present additional safety and efficacy results from its pivotal Phase 3 BROOKLYN, BROADWAY and TANDEM trials at the 2025 American Heart Association Scientific Sessions in New Orleans, November 7–10, 2025.
Oral presentation: ‘‘CETP Inhibition with Obicetrapib Produces Substantial Reductions in LDL Particles: Pooled Analysis of BROOKLYN and BROADWAY’’ by John Kastelein on Nov 9, 2025 at 10:15am CT. Digital poster: obicetrapib plus ezetimibe data by Jose Inia on Nov 10, 2025 at 10:59am CT. Management will join three investor conference fireside chats Nov 11–19, 2025, with live webcasts and archived replays on the company IR site.
Caristo Diagnostics was chosen as the worldwide imaging core lab for NewAmsterdam Pharma (NASDAQ: NAMS) REMBRANDT Cardiovascular Imaging Trial announced Oct 14, 2025. Caristo will oversee all coronary plaque and inflammation measurements and monitoring across the study.
REMbrandT is a placebo-controlled, double-blind, randomized trial recruiting at 50 sites in 7 countries to assess obicetrapib+ezetimibe FDC. The primary endpoint is percent change in total noncalcified coronary atherosclerotic plaque volume (NCPV) at 18 months. Secondary endpoints include percent change in LDL-C and change in Caristo's proprietary FAI-Score for coronary inflammation.